Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

Plummer, Ruth; Vidal, Laura; Griffin, Melanie; Lesley, Mark; de Bono, Johann; Coulthard, Sally; Sludden, Julieann; Siu, Lillian L; Chen, Eric X; Oza, Amit M; Reid, Gregory K; McLeod, A Robert; Besterman, Jeffrey M; Lee, Chooi; Judson, Ian; Calvert, Hilary; Boddy, Alan V.
Clin Cancer Res; 15(9): 3177-83, 2009 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-19383817